IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
After setbacks, cema-cel might have a path to approval in lymphoma.
The oncolytic virus vuso-vec is slapped with its second CRL.
Optimum-02 virtually replicates phase 1, and a filing will follow.
The group impresses in ovarian and endometrial cancers.
After opting in last year, Gilead picks up Kymera's KT-200.
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
